Patients who received exemestane plus ovarian function suppression reported more vaginal dryness, greater loss of sexual interest, and more difficulties becoming aroused than did patients who received tamoxifen plus ovarian function suppression.
These differences persisted over time.
An increase in bone or joint pain was more pronounced, particularly in the short term, in patients who received exemestane plus ovarian function suppression than in patients who received tamoxifen plus ovarian function suppression.
Changes in global QOL indicators from baseline were small and similar between treatments over the 5 years.[59][Level of evidence A3] In postmenopausal women, the use of AIs in sequence with or as a substitute for tamoxifen has been the subject of multiple studies, the results of which have been summarized in an individual patient-level meta-analysis.[60] Evidence (AI vs.